FMP
Histogen Inc.
HSTO
NASDAQ
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.35 USD
0.1999 (57.11%)
About
ceo
Ms. Susan A. Knudson
sector
Healthcare
industry
Biotechnology
website
https://www.histogen.com
exchange
NASDAQ
Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen In...
CIK
0001383701
ISIN
US43358Y2028
CUSIP
43358Y103
Address
10655 Sorrento Valley Road
Phone
858 526 3100
Country
US
Employee
7
IPO Date
Jul 25, 2013
Summary
CIK
0001383701
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
43358Y103
ISIN
US43358Y2028
Country
US
Price
0.35
Beta
1.17
Volume Avg.
19.2k
Market Cap
1.5M
Shares
-
52-Week
0.05-1.05
DCF
5.92
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.12
P/B
-
Website
https://www.histogen.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest HSTO News
It looks like there's no news available.
